DK3091029T3 - Anti-IL13-antistofformuleringer - Google Patents
Anti-IL13-antistofformuleringer Download PDFInfo
- Publication number
- DK3091029T3 DK3091029T3 DK16169916.0T DK16169916T DK3091029T3 DK 3091029 T3 DK3091029 T3 DK 3091029T3 DK 16169916 T DK16169916 T DK 16169916T DK 3091029 T3 DK3091029 T3 DK 3091029T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody formulations
- antibody
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553916P | 2011-10-31 | 2011-10-31 | |
| EP12846324.7A EP2773662A4 (en) | 2011-10-31 | 2012-10-30 | ANTIBODY FORMULATIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3091029T3 true DK3091029T3 (da) | 2023-01-30 |
Family
ID=48192677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16169916.0T DK3091029T3 (da) | 2011-10-31 | 2012-10-30 | Anti-IL13-antistofformuleringer |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10000562B2 (da) |
| EP (3) | EP3091029B1 (da) |
| JP (4) | JP6120452B2 (da) |
| KR (4) | KR101994809B1 (da) |
| CN (4) | CN104039826A (da) |
| AR (2) | AR088579A1 (da) |
| AU (3) | AU2012332767C1 (da) |
| CA (2) | CA2849210C (da) |
| DK (1) | DK3091029T3 (da) |
| ES (1) | ES2936387T3 (da) |
| FI (1) | FI3091029T3 (da) |
| HK (1) | HK1201857A1 (da) |
| HR (1) | HRP20230153T1 (da) |
| HU (1) | HUE061728T2 (da) |
| IL (2) | IL232053B (da) |
| LT (1) | LT3091029T (da) |
| MX (2) | MX363226B (da) |
| MY (2) | MY197851A (da) |
| PL (1) | PL3091029T3 (da) |
| PT (1) | PT3091029T (da) |
| RS (1) | RS63948B1 (da) |
| RU (1) | RU2665810C2 (da) |
| SG (1) | SG11201401903PA (da) |
| SI (1) | SI3091029T1 (da) |
| WO (1) | WO2013066866A1 (da) |
| ZA (2) | ZA201401779B (da) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| AU2012333210B2 (en) | 2011-06-24 | 2017-01-19 | Solventum Intellectual Properties Company | Reduced-pressure dressings employing tissue-fixation elements |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SG10201602654SA (en) | 2011-10-03 | 2016-05-30 | Moderna Therapeutics Inc | Modified nucleosides,nucleotides,and nucleic acids,and uses thereof |
| SI2771031T1 (en) | 2011-10-28 | 2018-08-31 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| KR101994809B1 (ko) * | 2011-10-31 | 2019-07-01 | 제넨테크, 인크. | 항체 제제 |
| WO2013090648A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
| EP2807188B1 (en) | 2012-01-27 | 2019-09-11 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| JP2015516143A (ja) | 2012-04-02 | 2015-06-08 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
| EP3043820A4 (en) * | 2013-09-13 | 2017-07-12 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| AU2014329452B2 (en) | 2013-10-03 | 2019-06-20 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| JPWO2015079977A1 (ja) * | 2013-11-26 | 2017-03-16 | シャープ株式会社 | 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット |
| JP6744856B2 (ja) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| KR102557798B1 (ko) | 2014-12-23 | 2023-07-19 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 독소 사전충전된 용기 |
| EP3528838B1 (en) * | 2016-09-23 | 2023-07-19 | F. Hoffmann-La Roche AG | Uses of il-13 antagonists for treating atopic dermatitis |
| AU2018207367B2 (en) * | 2017-01-11 | 2024-02-15 | Celltrion Inc. | Stable Liquid Formula |
| JP2019048091A (ja) * | 2018-10-23 | 2019-03-28 | ニプロ株式会社 | デクスメデトミジン注射液を充填したプレフィルドシリンジ |
| AU2019333836B2 (en) * | 2019-01-02 | 2023-11-09 | Tosoh Corporation | Light scattering detectors and methods for the same |
| AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
| KR20220122993A (ko) * | 2019-11-26 | 2022-09-05 | 코메라 라이프 사이언시스, 인코포레이티드 | 바이오폴리머 제형을 위한 부형제 화합물 |
| CA3199246A1 (en) * | 2020-10-22 | 2022-04-28 | Allakos Inc. | Anti-siglec-8 antibody formulations |
| TW202317191A (zh) | 2021-07-16 | 2023-05-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
| TW202323291A (zh) | 2021-08-13 | 2023-06-16 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
| IL311027A (en) | 2021-09-15 | 2024-04-01 | Dermira Inc | IL-13 inhibitors for the treatment of PRURIGO NODULARIS |
| WO2023215769A1 (en) | 2022-05-05 | 2023-11-09 | Dermira, Inc. | Il-13 antibodies for the treatment of atopic dermatitis |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0318512B1 (en) | 1986-08-18 | 1998-06-17 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
| JPH08503950A (ja) | 1992-12-02 | 1996-04-30 | アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド | 徐放性成長ホルモン含有マイクロスフェア |
| NZ292263A (en) | 1994-09-09 | 1998-12-23 | Takeda Chemical Industries Ltd | Sustained release preparations comprising a polyvalent metal salt of water-soluble peptide and a biodegradable polymer |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU708756B2 (en) | 1995-06-07 | 1999-08-12 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| KR100643058B1 (ko) | 1996-12-03 | 2006-11-13 | 아브게닉스, 인크. | 복수의 Ｖн 및 Ｖк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체 |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
| US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
| EP1324776B2 (en) | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| MXPA04003901A (es) * | 2001-11-07 | 2004-07-08 | Cytos Biotechnology Ag | Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas. |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| EP1603596B1 (en) | 2003-02-28 | 2008-05-07 | Ares Trading S.A. | Liquid formulations of tumor necrosis factor-binding protein tbp-1 |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| LT2335725T (lt) | 2003-04-04 | 2017-01-25 | Genentech, Inc. | Didelės koncentracijos antikūno ir baltymo kompozicijos |
| AR045614A1 (es) * | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
| DK1711528T3 (da) * | 2003-12-23 | 2012-08-20 | Genentech Inc | Behandling af cancer med hidtil ukendte anti-il 13 monoklonale antistoffer |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP1942939B2 (en) | 2005-09-30 | 2021-07-07 | Medimmune Limited | Interleukin-13 antibody composition |
| PE20080036A1 (es) * | 2005-10-21 | 2008-03-06 | Novartis Ag | Anticuerpos humanos para la interleucina-13 (il13) |
| BRPI0620316A2 (pt) * | 2005-12-21 | 2011-11-08 | Wyeth Corp | formulações de proteìnas com viscosidades reduzida e seus usos |
| TWI395754B (zh) * | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| MX2009007406A (es) * | 2007-01-09 | 2010-01-25 | Wyeth Corp | Formulaciones de anticuerpo anti-il-13 y usos de las mismas. |
| CA2676881C (en) * | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| KR101688038B1 (ko) * | 2008-12-03 | 2016-12-20 | 아스텔라스 도이칠란트 게엠베하 | 벤다무스틴의 경구 투약 형태 |
| CN102414221A (zh) * | 2009-03-06 | 2012-04-11 | 健泰科生物技术公司 | 抗体配制剂 |
| EP3216462A3 (en) | 2010-02-26 | 2017-12-20 | Novo Nordisk A/S | Stable antibody containing compositions |
| MX354867B (es) * | 2010-03-22 | 2018-03-23 | Genentech Inc Star | Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína. |
| JP2013525484A (ja) | 2010-05-03 | 2013-06-20 | ジェネンテック， インコーポレイテッド | タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法 |
| JP6024025B2 (ja) | 2011-05-02 | 2016-11-09 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 少容量投与用のアロタイプ選択抗体の限外濾過濃縮 |
| KR101994809B1 (ko) | 2011-10-31 | 2019-07-01 | 제넨테크, 인크. | 항체 제제 |
-
2012
- 2012-10-30 KR KR1020177022308A patent/KR101994809B1/ko active IP Right Grant
- 2012-10-30 CN CN201280053245.XA patent/CN104039826A/zh active Pending
- 2012-10-30 RU RU2014116070A patent/RU2665810C2/ru active
- 2012-10-30 CN CN201810964731.6A patent/CN109078182B/zh active Active
- 2012-10-30 PT PT161699160T patent/PT3091029T/pt unknown
- 2012-10-30 FI FIEP16169916.0T patent/FI3091029T3/fi active
- 2012-10-30 WO PCT/US2012/062572 patent/WO2013066866A1/en active Application Filing
- 2012-10-30 ES ES16169916T patent/ES2936387T3/es active Active
- 2012-10-30 PL PL16169916.0T patent/PL3091029T3/pl unknown
- 2012-10-30 DK DK16169916.0T patent/DK3091029T3/da active
- 2012-10-30 KR KR1020207015572A patent/KR102259829B1/ko active IP Right Grant
- 2012-10-30 SI SI201232018T patent/SI3091029T1/sl unknown
- 2012-10-30 CN CN201810964732.0A patent/CN108704132A/zh active Pending
- 2012-10-30 MY MYPI2018001912A patent/MY197851A/en unknown
- 2012-10-30 MY MYPI2014001225A patent/MY187874A/en unknown
- 2012-10-30 LT LTEP16169916.0T patent/LT3091029T/lt unknown
- 2012-10-30 KR KR1020197018310A patent/KR20190077127A/ko not_active Application Discontinuation
- 2012-10-30 JP JP2014539136A patent/JP6120452B2/ja active Active
- 2012-10-30 EP EP16169916.0A patent/EP3091029B1/en active Active
- 2012-10-30 MX MX2014004992A patent/MX363226B/es unknown
- 2012-10-30 HR HRP20230153TT patent/HRP20230153T1/hr unknown
- 2012-10-30 CA CA2849210A patent/CA2849210C/en active Active
- 2012-10-30 AR ARP120104056 patent/AR088579A1/es not_active Application Discontinuation
- 2012-10-30 CA CA3078979A patent/CA3078979C/en active Active
- 2012-10-30 KR KR20147011246A patent/KR20140084078A/ko active Search and Examination
- 2012-10-30 EP EP22208284.4A patent/EP4218937A3/en active Pending
- 2012-10-30 SG SG11201401903PA patent/SG11201401903PA/en unknown
- 2012-10-30 RS RS20230095A patent/RS63948B1/sr unknown
- 2012-10-30 HU HUE16169916A patent/HUE061728T2/hu unknown
- 2012-10-30 EP EP12846324.7A patent/EP2773662A4/en not_active Withdrawn
- 2012-10-30 AU AU2012332767A patent/AU2012332767C1/en active Active
- 2012-10-30 CN CN202210876554.2A patent/CN116077644A/zh active Pending
-
2014
- 2014-03-11 ZA ZA2014/01779A patent/ZA201401779B/en unknown
- 2014-04-10 IL IL232053A patent/IL232053B/en active IP Right Grant
- 2014-04-23 US US14/259,882 patent/US10000562B2/en active Active
- 2014-04-24 MX MX2019002979A patent/MX2019002979A/es unknown
-
2015
- 2015-03-09 HK HK15102358.5A patent/HK1201857A1/xx unknown
-
2016
- 2016-06-08 JP JP2016114267A patent/JP6272950B2/ja active Active
- 2016-08-05 AU AU2016210757A patent/AU2016210757A1/en not_active Abandoned
-
2017
- 2017-10-18 JP JP2017202159A patent/JP2018048166A/ja not_active Withdrawn
-
2018
- 2018-06-07 US US16/002,932 patent/US10947307B2/en active Active
- 2018-09-19 AU AU2018232943A patent/AU2018232943B2/en active Active
-
2019
- 2019-03-11 ZA ZA2019/01490A patent/ZA201901490B/en unknown
- 2019-06-25 JP JP2019116979A patent/JP6921148B2/ja active Active
-
2020
- 2020-07-22 IL IL276234A patent/IL276234B/en unknown
-
2021
- 2021-02-04 US US17/167,754 patent/US20210155684A1/en active Pending
- 2021-11-24 AR ARP210103246A patent/AR124140A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3091029T3 (da) | Anti-IL13-antistofformuleringer | |
| DK3117837T3 (da) | Antistofformuleringer | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| DK3275892T3 (da) | Præfusions-rsv-f-antigener | |
| BR112013022102A2 (pt) | composição | |
| BR112014002399A2 (pt) | conjunto | |
| DK2686017T3 (da) | Oftalmisk sammensætning | |
| CO6801637A2 (es) | Formulaciones de anticuerpos | |
| BR112014004395A2 (pt) | composição | |
| BR112014000879A2 (pt) | deflegmador | |
| CO6940426A2 (es) | Formulaciones farmacéuticas | |
| CO6960543A2 (es) | 2-tiopirimidinonas | |
| BR112014000015A2 (pt) | formulação | |
| BR112013033808A2 (pt) | composição | |
| DE102011100082A8 (de) | Traygreifvorrichtung | |
| BR112014005756A2 (pt) | vacina | |
| DK2690985T3 (da) | Møbel | |
| CO6761402A2 (es) | Formulaciones inmunosupresoras | |
| BR112014007030A2 (pt) | composição | |
| FR2978964B1 (fr) | Composition vaccinale anti-il-6 | |
| DK2672817T3 (da) | Forbedrede insekticide formuleringer | |
| DE112012000958A5 (de) | Handsäge | |
| DE112012000819A5 (de) | Gurtbandfänger | |
| BR112013022907A2 (pt) | composição farmacêutica | |
| FR2974690B1 (fr) | Amplificateur |